{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:55Z","timestamp":1794047455762,"version":"4.8.0"},"reference-count":23,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT confers additional benefit following rituximab-based chemoimmunotherapy (CIT) induction in patients with limited stage disease. We conducted a multicenter, retrospective analysis of patients treated between 2005 and 2019 using rituximab-based CIT regimens with or without consolidative RT to discern whether consolidative RT adds benefit in patients with stage I-II disease that could be encompassed in one radiation field. A total of 112 patients were included: 78 received CIT and radiation (RT group), and 34 received CIT alone (no RT group). The overall survival at 10 years was 77.9% in the RT group and 89.0% in the no RT group (P=0.42). The relapse-free survival at 10 years was 73.5% in the RT group and 80.3% in the no RT group (P=0.88). Neither improved overall survival nor relapse-free survival was associated with the addition of consolidative RT. Subgroup analysis of patients only achieving a partial response after CIT suggests that these patients may benefit from consolidative RT.<\/jats:p>","DOI":"10.3324\/haematol.2023.283210","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T03:37:36Z","timestamp":1697686656000},"page":"1439-1444","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study"],"prefix":"10.3324","volume":"109","author":[{"given":"Alexandra","family":"Rezazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan Mullick","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiruni","family":"Mendries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista M.","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Monahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Siker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"60520","doi-asserted-by":"crossref","unstructured":"Messina C, Christie D, Zucca E, Gospodarowicz M, Ferreri AJ. Primary and secondary bone lymphomas. Cancer Treat Rev. 2015; 41(3):235-246.","DOI":"10.1016\/j.ctrv.2015.02.001"},{"key":"60521","doi-asserted-by":"crossref","unstructured":"Choi JY, Hahn JS, Suh CO, Yang WI. Primary lymphoma of bone-survival and prognosis. Korean J Intern Med. 2002; 17(3):191-197.","DOI":"10.3904\/kjim.2002.17.3.191"},{"key":"60522","doi-asserted-by":"crossref","unstructured":"Yohannan B, Rios A. Primary diffuse large B-cell lymphoma of the bone. J Hematol. 2023; 12(2):75-81.","DOI":"10.14740\/jh1087"},{"key":"60523","doi-asserted-by":"crossref","unstructured":"de Leval L, Braaten KM, Ancukiewicz M. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. Am J Surg Pathol. 2003; 27(9):1269-1277.","DOI":"10.1097\/00000478-200309000-00011"},{"key":"60524","doi-asserted-by":"crossref","unstructured":"Dubey P, Ha CS, Besa PC. Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys. 1997; 37(5):1087-1093.","DOI":"10.1016\/S0360-3016(97)00106-5"},{"key":"60525","doi-asserted-by":"crossref","unstructured":"Miller TP, Dahlberg S, Cassady JR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998; 339(1):21-26.","DOI":"10.1056\/NEJM199807023390104"},{"key":"60526","doi-asserted-by":"crossref","unstructured":"Coiffier B, Lepage E, Briere J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-242.","DOI":"10.1056\/NEJMoa011795"},{"key":"60527","doi-asserted-by":"crossref","unstructured":"Feugier P, Van Hoof A, Sebban C. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005; 23(18):4117-4126.","DOI":"10.1200\/JCO.2005.09.131"},{"key":"60528","doi-asserted-by":"crossref","unstructured":"Habermann TM, Weller EA, Morrison VA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-3127.","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"60529","doi-asserted-by":"crossref","unstructured":"Persky DO, Unger JM, Spier CM. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008; 26(14):2258-2263.","DOI":"10.1200\/JCO.2007.13.6929"},{"key":"60530","doi-asserted-by":"crossref","unstructured":"Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer. 2006; 106(12):2652-2656.","DOI":"10.1002\/cncr.21930"},{"key":"60531","doi-asserted-by":"crossref","unstructured":"Fidias P, Spiro I, Sobczak ML. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys. 1999; 45(5):1213-1218.","DOI":"10.1016\/S0360-3016(99)00305-3"},{"key":"60532","doi-asserted-by":"crossref","unstructured":"Barbieri E, Cammelli S, Mauro F. Primary non-Hodgkin\u2019s lymphoma of the bone: treatment and analysis of prognostic factors for stage I and stage II. Int J Radiat Oncol Biol Phys. 2004; 59(3):760-764.","DOI":"10.1016\/j.ijrobp.2003.11.020"},{"key":"60533","doi-asserted-by":"crossref","unstructured":"Tao R, Allen PK, Rodriguez A. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015; 92(1):122-129.","DOI":"10.1016\/j.ijrobp.2015.01.014"},{"key":"60534","doi-asserted-by":"crossref","unstructured":"Ma S, Zhang Y, Li Z. Role of radiation therapy differs between stages in primary bone large B-cell lymphoma in rituximab era: a population-based analysis. Front Oncol. 2020; 10:1157.","DOI":"10.3389\/fonc.2020.01157"},{"key":"60535","doi-asserted-by":"crossref","unstructured":"Cai L, Stauder MC, Zhang YJ. Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) study. Int J Radiat Oncol Biol Phys. 2012; 83(1):284-291.","DOI":"10.1016\/j.ijrobp.2011.06.1976"},{"key":"60536","doi-asserted-by":"crossref","unstructured":"Persky DO, Li H, Stephens DM. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020; 38(26):3003-3011.","DOI":"10.1200\/JCO.20.00999"},{"key":"60537","doi-asserted-by":"crossref","unstructured":"Freeman CL, Savage KJ, Villa DR. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2021; 137(7):929-938.","DOI":"10.1182\/blood.2020005846"},{"key":"60538","doi-asserted-by":"crossref","unstructured":"Poeschel V, Held G, Ziepert M. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019; 394(10216):2271-2281.","DOI":"10.1016\/S0140-6736(19)33008-9"},{"key":"60539","doi-asserted-by":"crossref","unstructured":"Bruno-Ventre M, Ferreri AJ, Gospodarowicz M. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist. 2014; 19(3):291-298.","DOI":"10.1634\/theoncologist.2013-0249"},{"key":"60540","doi-asserted-by":"crossref","unstructured":"Christie D, Dear K, Le T. Limited chemotherapy and shrinking field radiotherapy for osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. Int J Radiat Oncol Biol Phys. 2011; 80(4):1164-1170.","DOI":"10.1016\/j.ijrobp.2010.03.036"},{"key":"60541","unstructured":"National Comprehensive Cancer Network. B Cell Lymphomas. 2023."},{"key":"60542","doi-asserted-by":"crossref","unstructured":"Lee JW, Prosnitz LR, Stefanovic A, Kelsey CR. Are higher doses of consolidation radiation therapy necessary in diffuse large B-cell lymphoma involving osseous sites?. Adv Radiat Oncol. 2019; 4(3):507-512.","DOI":"10.1016\/j.adro.2019.03.010"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283210\/76174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283210\/76937","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11306\/76174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:06Z","timestamp":1794045906000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283210","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}